| Literature DB >> 23741022 |
Qiwen Yang1, Hui Zhang1, Yao Wang1, Yingchun Xu1, Minjun Chen1, Robert E Badal2, Hui Wang3, Yuxing Ni4, Yunsong Yu5, Bijie Hu6, Ziyong Sun7, Wenxiang Huang8, Yong Wang9, Anhua Wu10, Xianju Feng11, Kang Liao12, Dingxia Shen13, Zhidong Hu14, Yunzhuo Chu15, Juan Lu16, Bin Cao17, Jianrong Su18, Bingdong Gui19, Qiong Duan20, Shufang Zhang21, Haifeng Shao22, Haishen Kong23, Yunjian Hu24, Huifen Ye25.
Abstract
The objective of this study was to investigate the susceptibility of hospital-associated (HA) and community-associated (CA) Escherichia coli and Klebsiella pneumoniae isolated from patients with intra-abdominal infections (IAIs) in China. From 2002 to 2011, the minimum inhibitory concentrations (MICs) of 12 antibiotics against 3074 E. coli and 1025 K. pneumoniae from 23 centres located in 16 cities were determined by the broth microdilution method. During the 10 year study period, ertapenem, imipenem, amikacin and piperacillin-tazobactam retained high and stable activity against E. coli and K. pneumoniae isolates regardless of whether their source was HA or CA and regardless of their extended-spectrum beta-lactamase (ESBL) production. However, the susceptibility of E. coli to cephalosporins and ampicillin-sulbactam decreased dramatically during the 10 years, especially for the CA isolates. Fluoroquinolones showed low activity against E. coli. During the whole study period, the ESBL rates for E. coli isolates from IAIs increased from 36.1 % in 2002-2003 to 68.1 % in 2010-2011 (P<0.001). Correspondingly, the ESBL rates in HA isolates increased from 52.2 % in 2002-2003 to 70.0 % in 2010-2011 (P = 0.001), and in CA isolates from 19.1 % in 2002-2003 to 61.6 % in 2010-2011 (P<0.001). The ESBL-positive rate in K. pneumoniae remained between 30.1 and 39.3 % of the total isolates with no significant change during the 10 years. In conclusion, carbapenems retained the highest susceptibility rates against HA and CA E. coli and K. pneumoniae. High prevalence of ESBL in HA E. coli and fast-growing resistance in CA E. coli severely limit the empirical use of the third- and fourth-generation cephalosporins in the therapy of IAIs.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23741022 DOI: 10.1099/jmm.0.059816-0
Source DB: PubMed Journal: J Med Microbiol ISSN: 0022-2615 Impact factor: 2.472